QUICK SNAPSHOT

CJC-1295

GH Secretagogues

FDA Status
Not FDA-Approved

Phase II trial halted after patient fatality

Claimed Benefits
  • Sustained GH elevation
  • Preserved pulsatile GH secretion
  • Potential IGF-1 increase
Clinical Evidence
3
Human Trials
Phase I
Highest Phase

Phase I trials showed 2-10x GH increases lasting 6+ days, but development was suspended after a Phase II fatality.

Read Full Deep Dive

Mechanism, dosing, vendor pricing, and full research citations

Monthly Digest

Stay ahead of the market

New peptide profiles, vendor pricing shifts, and research updates. No spam, unsubscribe anytime.